Search Results - "Strum, Jay C."

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy by ROBERTS, Patrick J, BISI, John E, STRUM, Jay C, COMBEST, Austin J, DARR, David B, USARY, Jerry E, ZAMBONI, William C, WONG, Kwok-Kin, PEROU, Charles M, SHARPLESS, Norman E

“…Cyclin-dependent kinases (CDKs) regulate cell proliferation and coordinate the cell cycle checkpoint response to DNA damage. Although inhibitors with varying…”
Get full text

MicroRNA 132 Regulates Nutritional Stress-Induced Chemokine Production through Repression of SirT1 by Strum, Jay C, Johnson, Jennifer H, Ward, James, Xie, Hongbo, Feild, John, Hester, Austin, Alford, Alexander, Waters, K. Michelle

“…Human adipose tissue secretes a number of proinflammatory mediators that may contribute to the pathophysiology of obesity-related disorders. Understanding the…”
Get full text

Adipose Mitochondrial Biogenesis Is Suppressed in db/db and High-Fat Diet–Fed Mice and Improved by Rosiglitazone by RONG, James X, YANG QIU, STRUM, Jay C, RYAN, Terence E, HANSEN, Michael K, LEI ZHU, ZHANG, Vivian, MI XIE, OKAMOTO, Yuji, MATTIE, Michael D, HIGASHIYAMA, Hiroyuki, ASANO, Satoshi

“…Adipose Mitochondrial Biogenesis Is Suppressed in db/db and High-Fat Diet–Fed Mice and Improved by Rosiglitazone James X. Rong 1 , Yang Qiu 2 3 , Michael K…”
Get full text

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy by Lai, Anne Y, Sorrentino, Jessica A, Dragnev, Konstantin H, Weiss, Jared M, Owonikoko, Taofeek K, Rytlewski, Julie A, Hood, Jill, Yang, Zhao, Malik, Rajesh K, Strum, Jay C, Roberts, Patrick J

“…Combination treatment with chemotherapy and immune checkpoint inhibitors (ICIs) has demonstrated meaningful clinical benefit to patients. However,…”
Get full text

Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men by RISERUS, Ulf, SPRECHER, Dennis, STRUM, Jay C, BASU, Samar, CHEESEMAN, Jane, FIELDING, Barbara A, HUMPHREYS, Sandy M, DANOFF, Theodore, MOORE, Niall R, MURGATROYD, Peter, O'RAHILLY, Stephen, SUTTON, Pauline, JOHNSON, Tony, WILLSON, Tim, HASSALL, David, FRAYN, Keith N, KARPE, Fredrik, OLSON, Eric, HIRSCHBERG, Sandra, AIXUE LIU, ZEKE FANG, HEGDE, Priti, RICHARDS, Duncan, SAROV-BLAT, Leli

“…Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases…”
Get full text

The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids by Brown, Andrew J, Goldsworthy, Susan M, Barnes, Ashley A, Eilert, Michelle M, Tcheang, Lili, Daniels, Dion, Muir, Alison I, Wigglesworth, Mark J, Kinghorn, Ian, Fraser, Neil J, Pike, Nicholas B, Strum, Jay C, Steplewski, Klaudia M, Murdock, Paul R, Holder, Julie C, Marshall, Fiona H, Szekeres, Philip G, Wilson, Shelagh, Ignar, Diane M, Foord, Steve M, Wise, Alan, Dowell, Simon J

“…GPR41 and GPR43 are related members of a homologous family of orphan G protein-coupled receptors that are tandemly encoded at a single chromosomal locus in…”
Get full text

The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids by Briscoe, Celia P, Tadayyon, Mohammad, Andrews, John L, Benson, William G, Chambers, Jon K, Eilert, Michelle M, Ellis, Catherine, Elshourbagy, Nabil A, Goetz, Aaron S, Minnick, Dana T, Murdock, Paul R, Sauls, Jr, Howard R, Shabon, Usman, Spinage, Lisa D, Strum, Jay C, Szekeres, Philip G, Tan, Kong B, Way, James M, Ignar, Diane M, Wilson, Shelagh, Muir, Alison I

“…GPR40 is a member of a subfamily of homologous G protein-coupled receptors that include GPR41 and GPR43 and that have no current function or ligand ascribed…”
Get full text

CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC by Stice, James P, Wardell, Suzanne E, Norris, John D, Yllanes, Alexander P, Alley, Holly M, Haney, Victoria O, White, Hannah S, Safi, Rachid, Winter, Peter S, Cocce, Kimberly J, Kishton, Rigel J, Lawrence, Scott A, Strum, Jay C, McDonnell, Donald P

“…Resistance to second-generation androgen receptor (AR) antagonists and CYP17 inhibitors in patients with castration-resistant prostate cancer (CRPC) develops…”
Get full text

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation by Deng, Jiehui, Wang, Eric S, Jenkins, Russell W, Li, Shuai, Dries, Ruben, Yates, Kathleen, Chhabra, Sandeep, Huang, Wei, Liu, Hongye, Aref, Amir R, Ivanova, Elena, Paweletz, Cloud P, Bowden, Michaela, Zhou, Chensheng W, Herter-Sprie, Grit S, Sorrentino, Jessica A, Bisi, John E, Lizotte, Patrick H, Merlino, Ashley A, Quinn, Max M, Bufe, Lauren E, Yang, Annan, Zhang, Yanxi, Zhang, Hua, Gao, Peng, Chen, Ting, Cavanaugh, Megan E, Rode, Amanda J, Haines, Eric, Roberts, Patrick J, Strum, Jay C, Richards, William G, Lorch, Jochen H, Parangi, Sareh, Gunda, Viswanath, Boland, Genevieve M, Bueno, Raphael, Palakurthi, Sangeetha, Freeman, Gordon J, Ritz, Jerome, Haining, W Nicholas, Sharpless, Norman E, Arthanari, Haribabu, Shapiro, Geoffrey I, Barbie, David A, Gray, Nathanael S, Wong, Kwok-Kin

“…Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the…”
Get more information

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression by Bisi, John E, Sorrentino, Jessica A, Roberts, Patrick J, Tavares, Francis X, Strum, Jay C

“…Chemotherapy-induced myelosuppression continues to represent the major dose-limiting toxicity of cytotoxic chemotherapy, which can be manifested as…”
Get full text

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion by He, Shenghui, Roberts, Patrick J, Sorrentino, Jessica A, Bisi, John E, Storrie-White, Hannah, Tiessen, Renger G, Makhuli, Karenann M, Wargin, William A, Tadema, Henko, van Hoogdalem, Ewoud-Jan, Strum, Jay C, Malik, Rajesh, Sharpless, Norman E

“…Conventional cytotoxic chemotherapy is highly effective in certain cancers but causes dose-limiting damage to normal proliferating cells, especially…”
Get more information

Rosiglitazone Induces Mitochondrial Biogenesis in Differentiated Murine 3T3-L1 and C3H/10T1/2 Adipocytes by Kashatus, Jennifer A., Remlinger, Katja S., Bing, Nan, Crosby, Renae M., Jackson, Tymissha K., Witherspoon, Sam M., Moore, John T., Ryan, Terence E., Neill, Sue D., Strum, Jay C., Rong, James X., Zhang, Vivian, Waters, K. Michelle, Johnson, Jennifer H., Klein, Jean-Louis D., Qiu, Yang, Xie, Mi

“…Growing evidence indicates that PPARγ agonists, including rosiglitazone (RSG), induce adipose mitochondrial biogenesis. By systematically analyzing…”
Get full text

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer by Andreano, Kaitlyn J., Wardell, Suzanne E., Baker, Jennifer G., Desautels, Taylor K., Baldi, Robert, Chao, Christina A., Heetderks, Kendall A., Bae, Yeeun, Xiong, Rui, Tonetti, Debra A., Gutgesell, Lauren M., Zhao, Jiong, Sorrentino, Jessica A., Thompson, Delita A., Bisi, John E., Strum, Jay C., Thatcher, Gregory R. J., Norris, John D.

“…Purpose The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy…”
Get full text

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors by Bisi, John E, Sorrentino, Jessica A, Jordan, Jamie L, Darr, David D, Roberts, Patrick J, Tavares, Francis X, Strum, Jay C

“…Inhibition of the p16INK4a/cyclin D/CDK4/6/RB pathway is an effective therapeutic strategy for the treatment of estrogen receptor positive (ER+) breast cancer…”
Get full text

Rosiglitazone induces mitochondrial biogenesis in mouse brain by Strum, Jay C, Shehee, Ron, Virley, David, Richardson, Jill, Mattie, Michael, Selley, Paula, Ghosh, Sujoy, Nock, Christina, Saunders, Ann, Roses, Allen

“…Rosiglitazone was found to simulate mitochondrial biogenesis in mouse brain in an apolipoprotein (Apo) E isozyme-independent manner. Rosiglitazone induced both…”
Get more information

Recovery and Expression of Messenger RNA from Postmortem Human Brain Tissue by Cummings, Thomas J, Strum, Jay C, Yoon, Lawrence W, Szymanski, Mari H, Hulette, Christine M

“…The Bryan Alzheimer's Disease Research Center Rapid Autopsy Program at Duke University Medical Center obtains postmortem human brain tissue for experimental…”
Get full text

Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors by Hall, Claire R., Bisi, John E., Strum, Jay C.

“…Abstract The cyclin dependent kinase (CDK) family of proteins is associated with cell cycle progression and transcriptional regulation. Abnormalities in the…”
Get full text

Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats by Yang, Baichun, Brown, Kathleen K, Chen, Lihong, Carrick, Kevin M, Clifton, Lisa G, McNulty, Judi A, Winegar, Deborah A, Strum, Jay C, Stimpson, Stephen A, Pahel, Gregory L

“…PPARgamma agonists ameliorate insulin resistance and dyslipidemia in type 2 diabetic patients. Adiponectin possesses insulin sensitizing properties, and…”
Get full text

Abstract 4426: Selective inhibition of CDK9 induces apoptosis of TNBC cells independent of Rb status by Brighton, Hailey E., Hall, Claire R., Dillon, Kerry A., Bisi, John E., Strum, Jay C.

“…Abstract The family of cyclin-dependent kinases (CDKs) are serine/threonine protein kinases important for cell cycle control and/or regulation of…”
Get full text

Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer by Freed, Daniel M., Hall, Claire R., Strum, Jay C., Roberts, Patrick J.

“…Abstract Tyrosine kinase inhibitors (TKIs) targeting oncogenes such as EGFR, ALK, or RET have dramatically improved anti-tumor efficacy in patients with…”
Get full text